Drug Type Synthetic peptide |
Synonyms Dual GLP-1R/GIPR agonists(Carmot Therapeutics), CT 868, CT868 |
Target |
Mechanism GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Start Date19 Oct 2023 |
Sponsor / Collaborator |
Start Date21 Mar 2023 |
Sponsor / Collaborator |
Start Date22 Feb 2022 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 1 | Phase 2 | US | 19 Oct 2023 | |
Diabetes Mellitus, Type 2 | Phase 2 | US | 22 Feb 2022 | |
Diabetes Mellitus, Type 2 | Phase 2 | MX | 22 Feb 2022 | |
Obesity | Phase 2 | US | 22 Feb 2022 | |
Obesity | Phase 2 | MX | 22 Feb 2022 | |
Overweight | Phase 2 | - | - | |
Nonalcoholic Steatohepatitis | Phase 1 | AU | - |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
NCT05110846 (ADA2023) Manual | Phase 2 | 103 | CT-868 1.75 mg | eidbtcnfer(fzjpaixeuq) = psxzqzdcys lxbrokgdbz (orblxsbgoi ) View more | Positive | 17 Oct 2023 | |
CT-868 3.25 mg | eidbtcnfer(fzjpaixeuq) = ubvfzhxlev lxbrokgdbz (orblxsbgoi ) View more | ||||||
Not Applicable | 20 | laxyjmlvbj(hnoswuolcf) = xbcvkpacxp mhdoudkhsz (ywtrntltzh ) View more | - | 20 Jun 2023 | |||
Placebo | laxyjmlvbj(hnoswuolcf) = bdgxhbymob mhdoudkhsz (ywtrntltzh ) View more |